Changes in mean serum lipids among adults in Germany: Results from National Health Surveys 1997-99 and 2008-11

BMC Public Health

Volumn 16, Issue 1, 2016, Pages

  Truthmann, Julia ^a   Schienkiewitz, Anja ^a   Busch, Markus A ^a   Mensink, Gert B M ^a   Du, Yong ^a   Bosy Westphal, Anja ^b   Knopf, Hildtraud ^a   Scheidt Nave, Christa ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

High density lipoprotein cholesterol; Lifestyle; Lipid lowering medication; Total cholesterol; Triglycerides

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; GERMANY; HEALTH SURVEY; HUMAN; LIFESTYLE; MALE; MIDDLE AGED; SEX DIFFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; GERMANY; HEALTH SURVEYS; HUMANS; LIFE STYLE; LIPIDS; MALE; MIDDLE AGED; SEX FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84960941442     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-016-2826-2     Document Type: Article

References (49)

1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2012. doi: 10.1093/eurheartj/ehs092.
2. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. The Lancet. 384(9943):626-35. doi: 10.1016/S0140-6736(14)61177-6.
3. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384(9943):618-25. doi: 10.1016/S0140-6736(14)61217-4.
4. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011;377(9765):578-86. doi: 10.1016/S0140-6736(10)62038-7.
5. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids. Nature. 2010;466(7307):707-13. doi: 10.1038/nature09270.
6. Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), vol 14. 2011.
7. Naz F, Jyoti S, Akhtar N, Afzal M, Siddique YH. Lipid profile of women using oral contraceptive pills. Pak J Biol Sci. 2012;15(19):947-50. doi: 10.3923/pjbs.2012.947.950.
8. Sai AJ, Gallagher JC, Fang X. Efect of Hormone therapy and calcitriol on serum lipid profile in postmenopausal elderly women: association with estrogen receptor alpha genotypes. Menopause (New York, NY). 2011;18(10):1101-12. doi: 10.1097/gme.0b013e318217d41d.
9. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am. 1994;78(1):117-41.
10. Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME. Trends in lipids and lipoproteins in US adults, 1988-2010. JAMA. 2012;308(15):1545-54. doi: 10.1001/jama.2012.13260.
11. Eliasson M, Janlert U, Jansson JH, Stegmayr B. Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med. 2006;260(6):551-9. doi: 10.1111/j.1365-2796.2006.01730.x.
12. Ferrières J, Bongard V, Dallongeville J, Arveiler D, Cottel D, Haas B, et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. Arch Cardiovasc Dis. 2009;102(4):293-301. doi: 10.1016/j.acvd.2009.02.002.
13. Valsta LM, Tapanainen H, Sundvall J, Laatikainen T, Männistö S, Pietinen P, et al. Explaining the 25-year decline of serum cholesterol by dietary changes and use of lipid-lowering medication in Finland. Public Health Nutr. 2010;13(Special Issue 6A):932-8. doi: 10.1017/S1368980010001126.
14. Laaser U, Breckenkamp J. Trends in risk factor control in Germany 1984-1998: high blood pressure and total cholesterol. vol 2. 2006.
15. Bellach BM, Knopf H, Thefeld W. The German Health Survey. 1997/98. Gesundheitswesen. 1998;60 Suppl 2:S59-68.
16. Scheidt-Nave C, Kamtsiuris P, Gosswald A, Holling H, Lange M, Busch MA, et al. German health interview and examination survey for adults (DEGS) - design, objectives and implementation of the first data collection wave. BMC Public Health. 2012;12:730. doi: 10.1186/1471-2458-12-730.
17. World Health Organization. Diet, nutrition and the prevention of chronic diseases. Report of the joint WHO/FAO expert consultation, vol. 916. Geneva: WHO Technical Report Series; 2003.
18. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30-42.
19. Rauber F, Campagnolo PDB, Hoffman DJ, Vitolo MR. Consumption of ultra-processed food products and its effects on children's lipid profiles: A longitudinal study. Nutr Metab Cardiovasc Dis. 2015;25(1):116-22. doi: 10.1016/j.numecd.2014.08.001.
20. Cai L, Ma D, Zhang Y, Liu Z, Wang P. The effect of coffee consumption on serum lipids: a meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2012;66(8):872-7.
21. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ. 2011;342:636. doi: 10.1136/bmj.d636.
22. Burger M, Mensink GB. High alcohol consumption in Germany: results of the German National Health Interview and Examination Survey 1998. Public Health Nutr. 2004;7(7):879-84. doi: 10.1079/PHN2004631.
23. World Health Organization. Obesity: preventing and managing the global epidemic, vol. 894. Geneva: WHO Technical Report Series; 2000.
24. Knopf H, Grams D. Medication use of adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5-6):868-77.
25. Brauns H, Steinmann S. Educational Reform in France, West-Germany, the United Kingdom and Hungary. Updating the CASMIN Educational Classification. ZUMA-Nachrichten. 1999;44:7-44.
26. Kamtsiuris P, Lange M, Hoffmann R, Schaffrath Rosario A, Dahm S, Kuhnert R, et al. The first wave of the German Health Interview and Examination Survey for Adults (DEGS1): sample design, response, weighting and representativeness. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013;56(5-6):620-30. doi: 10.1007/s00103-012-1650-9.
27. Klose G, Schwabe U. Lipidsenkende Mittel. In: Schwabe U, Paffrath D, editors. Arzneimittelverordnungsreport 2014. Aktuelle Daten, Kosten, Trends und Kommentare. Heidelberg: Springer Medizin Verlag; 2014.
28. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol. 2005;60(5):543-51. doi: 10.1111/j.1365-2125.2005.02478.x.
29. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). JAMA. 2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
30. Ford ES, Capewell S. Trends in total and low-density lipoprotein cholesterol among U.S. adults: contributions of changes in dietary fat intake and use of cholesterol-lowering medications. PLoS One. 2013;8(5):e65228. doi: 10.1371/journal.pone.0065228.
31. Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015;3:CD008226. doi: 10.1002/14651858.CD008226.pub3.
32. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr. 2010;91(3):502-9. doi: 10.3945/ajcn.2008.26285.
33. Ellison RC, Zhang Y, Qureshi MM, Knox S, Arnett DK, Province MA. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J. 2004;147(3):529-35. doi: 10.1016/j.ahj.2003.10.033.
34. Durstine JL, Grandjean P, Davis P, Ferguson M, Alderson N, DuBose K. Blood Lipid and Lipoprotein Adaptations to Exercise. Sports Med. 2001;31(15):1033-62. doi: 10.2165/00007256-200131150-00002.
35. Lampert T, von der Lippe E, Muters S. Prevalence of smoking in the adult population of Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013;56(5-6):802-8. doi: 10.1007/s00103-013-1698-1.
36. Krachler B, Eliasson MC, Johansson I, Hallmans G, Lindahl B. Trends in food intakes in Swedish adults 1986-1999: findings from the Northern Sweden MONICA (Monitoring of Trends and Determinants in Cardiovascular Disease) Study. Public Health Nutr. 2005;8(06):628-35. doi: 10.1079/PHN2004710.
37. Mensink GB, Beitz R. Food and nutrient intake in East and West Germany, 8 years after the reunification-The German Nutrition Survey 1998. Eur J Clin Nutr. 2004;58(7):1000-10. doi: 10.1038/sj.ejcn.1601923.
38. Max Rubner-Institut. Nationale Verzehrsstudie II. Ergebnisbericht Teil 2. Karlsruhe 2008.
39. Libuda L, Alexy U, Kersting M. Time trends in dietary fat intake in a sample of German children and adolescents between 2000 and 2010: not quantity, but quality is the issue. Br J Nutr. 2014;111(01):141-50. doi: 10.1017/S0007114513002031.
40. Mensink GBM, Truthmann J, Rabenberg M, Heidemann C, Haftenberger M, Schienkiewitz A, et al. Fruit and vegetable intake in Germany: Results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013;56(5-6):779-85. doi: 10.1007/s00103-012-1651-8.
41. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009;63(S2):S5-21.
42. Craig-Schmidt MC. World-wide consumption of trans fatty acids. Atheroscler Suppl. 2006;7(2):1-4. doi: 10.1016/j.atherosclerosissup.2006.04.001.
43. Stender S, Astrup A, Dyerberg J. A trans European Union difference in the decline in trans fatty acids in popular foods: a market basket investigation. BMJ Open. 2012;2(5):e000859. doi: 10.1136/bmjopen-2012-000859.
44. Bundesinstitut für Risikobewertung. [Höhe der derzeitigen trans-Fettsäureaufnahme in Deutschland ist gesundheitlich unbedenklich]. BfR Opinion No. 028/2013. 2013.
45. Mozaffarian D, Clarke R. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr. 2009;63 Suppl 2:S22-33. doi: 10.1038/sj.ejcn.1602976.
46. Du Y, Doren M, Melchert HU, Scheidt-Nave C, Knopf H. Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003. BMC Womens Health. 2007;7:19. doi: 10.1186/1472-6874-7-19.
47. Jansson J-H, Boman K, Messner T. Trends in blood pressure, lipids, lipoproteins and glucose metabolism in the Northern Sweden MONICA project 1986-99. Scand J Public Health. 2003;31(61 suppl):43-50. doi: 10.1080/14034950310001397.
48. Rehm J, Sempos C, Kohlmeier L, Myers G, Thefeld W, Gunter E, et al. A comparison of serum total cholesterol levels and their determinants between the Federal Republic of Germany and the United States. Eur J Epidemiol. 2000;16(7):669-75. doi: 10.1023/A:1007693009604.
49. Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr. 1994;48(5):305-25.